Roswell Park study: Targeting the E3 ligase activity of MDM2 could help control p53 protein

Roswell Park receives $7.7M for biobank

Rep. Tim Kennedy (NY-D) announced $7,731,872 in new federal funding for Roswell Park Comprehensive Cancer Center to renovate its newly integrated biobank, the Roswell Park Biorepository, made possible through the Office of the Director of NIH’s Research Facilities Construction Grants.

October 11, 2024

Vol.50 No.38

In Brief

Thomas Schwaab named medical director of ChristianaCare’s Helen F. Graham Cancer Center & Research Institute

Thomas Schwaab was named Bank of America Endowed Medical Director of ChristianaCare’s Helen F. Graham Cancer Center & Research institute.

September 13, 2024

Vol.50 No.34

Clinical Trials & Tribulations

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.

July 26, 2024

Vol.50 No.30

By Jacquelyn Cobb and Paul Goldberg

Clinical Roundup

Exscientia builds AWS AI-powered platform to advance drug discovery

Exscientia plc announced it will be expanding its work with Amazon Web Services to use the cloud provider’s artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation.

July 12, 2024

Vol.50 No.28

Drugs & Targets

Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program

Boehringer Ingelheim and OSE Immunotherapeutics SA, a clinical-stage biotech company, announced that Boehringer will be progressing their first-in-class SIRPα immuno-oncology program into the next phase in clinical development.

July 12, 2024

Vol.50 No.28

Roswell Park study: Targeting the E3 ligase activity of MDM2 could help control p53 protein

YOU MAY BE INTERESTED IN

Roswell Park receives $7.7M for biobank

Thomas Schwaab named medical director of ChristianaCare’s Helen F. Graham Cancer Center & Research Institute

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Exscientia builds AWS AI-powered platform to advance drug discovery

Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program

Renew today!

Subscriber content

Never miss an issue!

Login

Roswell Park study: Targeting the E3 ligase activity of MDM2 could help control p53 protein

YOU MAY BE INTERESTED IN

Roswell Park receives $7.7M for biobank

Thomas Schwaab named medical director of ChristianaCare’s Helen F. Graham Cancer Center & Research Institute

Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Exscientia builds AWS AI-powered platform to advance drug discovery

Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program

Never miss an issue!

Login

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC